|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.07.26 - 22:03
|
Tempus Reports Second Quarter 2026 Results (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026.
“Q2 was another exceptional quarter for us,” said Eric Lefkofsky, Founder and CEO of Tempus. “Our strategy is working given the investments we have made in AI over the past several years are driving some of the best growth rates we have seen in our two largest businesses - Oncology Diagnostics and Data Licensing.”
Second Quarter 2026 Highlights
Total revenue of $382.5 million, up 22% year-over-year
Oncology volume growth of 31% year-over-year, up from 28% last quarter
Molecular residual disease (MRD) volume was 9,000 tests, up from 6,500 last quarter
Data Licensing & Modeling (Insights) revenue up 36% year-over-year
Signed ~$200 million in new Data and Applications licenses
FDA approved xT Tumor Only which will migrate tissue testing to ADLT pricing
Successfully delivered our first oncology foun...
|
|
|
|
|
|
|
|
|
|
|
20.07.26 - 15:36
|
Übernahme durch Tempus AI: Personalis Aktie gibt trotz Prämie nach (Investing.com DE)
|
|
|
Die Aktie von Personalis fiel im vorbörslichen Handel um 6,2 %, nachdem Tempus AI die Unterzeichnung einer endgültigen Vereinbarung zur Übernahme des auf Genomik in der Präzisionsonkologie spezialisierten Unternehmens bekannt gab. Das Transaktionsvolumen beläuft sich auf rund 1,5 Mrd. US-Dollar, abzüglich der bereits bestehenden Beteiligung von Tempus. Die Übernahme ist als reiner Aktientausch strukturiert, wobei eine Option besteht, bis zu 50 % des Kaufpreises in bar zu leisten...
|
|
|
|
|
20.07.26 - 15:21
|
Tempus AI will AKTIONÄR-Tipp schlucken – 70 Prozent seit Ende Mai (Der Aktionaer)
|
|
|
Es gab bereits Gerüchte, doch nun ist es amtlich: Für die Aktionäre des Krebsgenomik-Spezialisten Personalis hat Tempus AI ein Übernahmeangebot vorgelegt. AKTIONÄR-Leser können sich auf ein ordentliches Kursplus seit der Empfehlung Ende Mai freuen. Die Aktie von Tempus AI hingegen wird in einer ersten Reaktion abgestraft und fällt zeitweise gut sieben Prozent....
|
|
|
20.07.26 - 14:39
|
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform (Business Wire)
|
|
|
Acquisition brings together Personalis' MRD technology with Tempus' commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth
Expands Tempus' reach across the cancer care continuum and accelerates access to industry-leading technology within the rapidly emerging MRD market, a $20 billion opportunityFREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that it has entered into a definitive agreement to be acquired by Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care. The acquisition will expand Tempus capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis and treatment selection, to recurrence and monitoring.
Under the terms of the agreement, Personalis shareholders will receive consideration of $16.25 per share of common stock, represent...
|
|
|
20.07.26 - 14:33
|
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform (Business Wire)
|
|
|
Acquisition brings together Personalis' MRD technology with Tempus' commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth
Expands Tempus' reach across the cancer care continuum and accelerates access to industry-leading technology within the rapidly emerging MRD market, a $20 billion opportunityCHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis and treatment selection, to recurrence and monitoring.
Under the terms of the agreement, Personalis shareholders will receive consideration of $16.25 per share of common stock, representing a total enterprise value of $1.5 billion, net of Tempus' exist...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
